A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2011
09/28/2011	EP2368878A1 Peptidomimetic protease inhibitors
09/28/2011	EP2368877A1 Chiral intermediates for the preparation of peptidomimetic protease inhibitors
09/28/2011	EP2368876A1 Derivatives of aminoindanes, their preparation and their application in therapeutics
09/28/2011	EP2368873A1 Improved crystalline material
09/28/2011	EP2368577A2 Methods for treating interleukin-6 related diseases
09/28/2011	EP2368566A1 Interleukin 21 and tyrosine kinase inhibitor combination therapy
09/28/2011	EP2368559A2 Composition for preventing or treating artherosclerosis
09/28/2011	EP2368558A1 Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates
09/28/2011	EP2368557A1 Methods of simultaneously treating ocular rosacea and acne rosacea
09/28/2011	EP2368556A1 An osmotic drug delivery system
09/28/2011	EP2368555A1 Compositions and methods of use of phorbolesters
09/28/2011	EP2368554A1 Pharmaceutical formulations containing methylnaltrexone
09/28/2011	EP2368553A1 Pharmaceutical formulations containing methylnaltrexone
09/28/2011	EP2368552A1 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
09/28/2011	EP2368551A2 Methods of use for cyclopamine analogs
09/28/2011	EP2368550A1 Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
09/28/2011	EP2368549A1 Treating hand-foot syndrome and related pathologies using clonidine or its derivatives
09/28/2011	EP2368548A1 Dry powder pharmaceutical composition for inhalation
09/28/2011	EP2368547A1 Antiviral compositions comprising geraniol and carvone
09/28/2011	EP2368546A2 Pharmaceutical composition for the controlled release of methylphenidate
09/28/2011	EP2368545A1 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
09/28/2011	EP2368544A1 Orally rapidly disintegrating tablet, and process for producing same
09/28/2011	EP2368543A1 Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
09/28/2011	EP2368440A1 Feed additive composition comprising an organic acid and and at least one adsorbed essential oil compound
09/28/2011	EP2368431A1 Immunostimulatory G,U-containing oligoribonucleotides
09/28/2011	EP2367939A1 Methods for diagnosing or treating prostate cancer
09/28/2011	EP2367933A1 Novel porcine circovirus type 2b isolate and uses thereof
09/28/2011	EP2367837A2 1'-substituted ribose 5'-polyphosphate analogs and their use as modulators of p2y receptor activity
09/28/2011	EP2367830A1 1-oxa-8-azaspiro [4, 5] decane- 8 -carboxamide compounds as faah inhibitors
09/28/2011	EP2367829A1 Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
09/28/2011	EP2367827A1 3-(3-pyrimidine-2-yl-benzyl)-ý1,2,4¨triazolo ý4,3-b¨pyridazine derivatives
09/28/2011	EP2367826A1 Modulators of amyloid beta.
09/28/2011	EP2367825A1 Fused imidazole carboxamides as trpv3 modulators
09/28/2011	EP2367824A2 Anti-viral compounds
09/28/2011	EP2367823A1 Anti-viral compounds
09/28/2011	EP2367822A1 Tricyclic azaindoles
09/28/2011	EP2367821A1 C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
09/28/2011	EP2367820A2 Novel antimicrobials
09/28/2011	EP2367818A1 8-azabicyclo ý3.2.1¨oct-2-ene derivatives and their use as mono-amine neurotransmitter re-uptake inhibitors
09/28/2011	EP2367817A1 Inhibitors of diacylglycerol acyltransferase
09/28/2011	EP2367816A1 Isatin derivatives for use as in vivo imaging agents
09/28/2011	EP2367815A1 Pyridazinone derivatives
09/28/2011	EP2367814A1 New compounds 578
09/28/2011	EP2367813A1 Antiviral compounds
09/28/2011	EP2367812A2 [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4trifluoromethoxy-1h-indol-3-yl]methanone as an inhibitor of mast cell tryptase
09/28/2011	EP2367809A1 Derivatives of ý(3-hydroxy-4 pyron-2-yl)methyl¨-amine and use thereof as anti-neoplastic drugs
09/28/2011	EP2367808A2 PROGESTATIONAL 3-(6,6-ETHYLENE-17b-HYDROXY-3-OXO-17a-PREGNA-4-ENE-17a-YL) PROPIONIC ACID g-LACTONES
09/28/2011	EP2367805A2 Modified actinomycin-based nucleic acid stains and methods of their use
09/28/2011	EP2367804A2 Process for preparing efavirenz polymorph
09/28/2011	EP2367803A1 Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases
09/28/2011	EP2367802A2 Tetrahydrotriazine compounds for treating diseases associated with ampk activity
09/28/2011	EP2367801A1 Polar quinazolines as liver x receptors ( lxrs ) modulators
09/28/2011	EP2367800A2 New compounds
09/28/2011	EP2367799A1 New compounds
09/28/2011	EP2367798A2 Treatment of amyotrophic lateral sclerosis
09/28/2011	EP2367797A1 Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
09/28/2011	EP2367796A1 Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino }-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one as agonist of the beta 2 adrenergic receptor
09/28/2011	EP2367793A1 Gpr120 receptor agonists and uses thereof
09/28/2011	EP2367791A1 Perindopril tosylate
09/28/2011	EP2367790A2 Substituted octahydrocyclopenta(c)pyrrol-4-amines as calcium channel blockers
09/28/2011	EP2367788A1 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
09/28/2011	EP2367787A1 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
09/28/2011	EP2367786A1 Novel 1 -alkyl- 3 -hydroxy- 3 -phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
09/28/2011	EP2367785A1 Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
09/28/2011	EP2367784A1 Bicyclic triterpenoid iripallidal as a novel antiglioma and antineoplastic therapy in vitro
09/28/2011	EP2367599A1 Inhibition of hdac2 to promote memory
09/28/2011	EP2367598A2 Inhibitors of diacylglycerol acyltransferase
09/28/2011	EP2367573A1 Liquid pharmaceutical compositions comprising a triptan compound and xylitol
09/28/2011	EP2367572A2 Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
09/28/2011	EP2367563A1 Method of modulating hsf-1
09/28/2011	EP2367557A1 Composition for the treatment of inflammatory diseases of the oral and pharyngeal cavity
09/28/2011	EP2367555A2 Regenerating and enhancing development of muscle tissue
09/28/2011	EP2367554A2 Bile acid recycling inhibitors for treatment of obesity and diabetes
09/28/2011	EP2367553A1 Combination therapy to enhace nk cell mediated cytotoxicty
09/28/2011	EP2367552A1 Silica-based antibacterial and antifungal nanoformulation
09/28/2011	EP2367551A1 S1p lyase inhibitors for the treatment of cerebral malaria
09/28/2011	EP2367550A1 Il-3 inhibitors in use for treatment of rheumatoid arthritis in an early stage
09/28/2011	EP2367549A1 Use of lipoic acid for treating or preventing degenerative joint conditions, osteoarthritis, cartilage damage, and related disorders in companion animals
09/28/2011	EP2367548A1 Medical dietary composition for treating neurodegenerative diseases
09/28/2011	EP2367547A1 L-lysine for improving normal cognitive functions
09/28/2011	EP2367546A1 Local anesthetic for relieving breast pain
09/28/2011	EP2367545A1 Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy
09/28/2011	EP2367544A2 Method of treatment of aggression
09/28/2011	EP2367543A2 5-ht2a and 5-ht2b receptor antagonist for treating stenosis of the spinal canal
09/28/2011	EP2367542A1 Oral dosage forms of bendamustine
09/28/2011	EP2367539A1 Novel composition for treatment of essential thrombocythemia
09/28/2011	EP2367538A2 Solid dosage forms of bendamustine
09/28/2011	EP2367537A1 Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
09/28/2011	EP2367536A1 Controlled release pharmaceutical compositions comprising o-desmethyl-venlafaxine
09/28/2011	EP2367535A2 Pancreatic tumour treatment
09/28/2011	EP2367534A2 Pharmaceutical compositions containing inulin as granulation carrier
09/28/2011	EP2367533A1 Solid composition containing the ingredient rasagiline
09/28/2011	EP2367529A1 Composition for the use to treat alzheimer' s disease
09/28/2011	EP2367528A1 Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye
09/28/2011	EP2367526A1 Compositions and methods for alleviating hyposalivation and for providing oral comfort
09/28/2011	EP2367449A1 Composition comprising isoflavones
09/28/2011	EP2367432A1 Infarct area perfusion-improving compositions and methods of vascular injury repair
09/28/2011	EP2367431A1 Organic compounds
09/28/2011	EP2367430A1 Organic compounds
09/28/2011	EP2367429A1 Organic compounds

1 ... 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 ... 7860